Antidepressant-like and anxiolytic-like effects following activation of the μ-δ Opioid receptor heteromer in the nucleus accumbens

Molecular Psychiatry

Volumn 19, Issue 9, 2014, Pages 986-994

  Kabli, N ^a,b   Nguyen, T ^a   Balboni, G ^c   O'Dowd, B F ^a,b   George, S R ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

anhedonia; emotion; G protein coupled receptor; heterooligomer; mood; ventral striatum

Indexed keywords

DELTA OPIATE RECEPTOR; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLORNITHYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; HETEROMER; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NALTRINDOLE; OLIGOMER; POLYMER; UFP 512; UNCLASSIFIED DRUG; 2',6'-DIMETHYLTYROSYL-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID (1H-BENZIMIDAZOL-2-YL)(CARBOXYMETHYL)METHYLAMIDE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZIMIDAZOLE DERIVATIVE; NARCOTIC ANTAGONIST; OLIGOPEPTIDE;

ADULT; ANHEDONIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DOSE RESPONSE; ELEVATED PLUS MAZE TEST; FORCED SWIM TEST; HUMAN; HUMAN CELL; HYPOPHAGIA; IN VITRO STUDY; LATENT PERIOD; LIGAND BINDING; MAJOR DEPRESSION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; TRANQUILIZING ACTIVITY; TREATMENT RESISTANT DEPRESSION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; ANXIETY; CELL MEMBRANE; DEPRESSION; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; MENTAL STRESS; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY; BENZIMIDAZOLES; CELL MEMBRANE; DEPRESSION; HEK293 CELLS; HUMANS; MALE; NARCOTIC ANTAGONISTS; NUCLEUS ACCUMBENS; OLIGOPEPTIDES; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; STRESS, PSYCHOLOGICAL;

EID: 84921715691     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2013.115     Document Type: Article

References (70)

1. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L et al. Evaluation of outcomes with citalopram for depression using measurementbased care in STAR∗D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40.
2. Darko DF, Risch SC, Gillin JC, Golshan S. Association of beta-endorphin with specific clinical symptoms of depression. Am J Psychiatry 1992; 149: 1162-1167.
3. Kennedy SE, Koeppe RA, Young EA, Zubieta JK. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry 2006; 63: 1199-1208.
4. Zubieta JK, Ketter TA, Bueller JA, Xu Y, Kilbourn MR, Young EA et al. Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. Arch Gen Psychiatry 2003; 60: 1145-1153.
5. Nyhuis PW, Gastpar M, Scherbaum N. Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy. J Clin Psychopharmacol 2008; 28: 593-595.
6. Bodkin JA, Zornberg GL, Lukas SE, Cole JO. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol 1995; 15: 49-57.
7. Emrich HM, Vogt P, Herz A, Kissling W. Antidepressant effects of buprenorphine. Lancet 1982; 2: 709.
8. Emrich HM. A possible role of opioid substances in depression. Adv Biochem Psychopharmacol 1982; 32: 77-84.
9. Emrich HM, Vogt P, Herz A. Possible antidepressive effects of opioids: action of buprenorphine. Ann N Y Acad Sci 1982; 398: 108-112.
10. Extein I, Pickar D, Gold MS, Gold PW, Pottash AL, Sweeney DR et al. Methadone and morphine in depression [proceedings]. Psychopharmacol Bull 1981; 17: 29-33.
11. Hegadoren KM, O'Donnell T, Lanius R, Coupland NJ, Lacaze-Masmonteil N. The role of beta-endorphin in the pathophysiology of major depression. Neuropeptides 2009; 43: 341-353.
12. Kabli N, Martin N, Fan T, Nguyen T, Hasbi A, Balboni G et al. Agonists at the delta-opioid receptor modify the binding of micro-receptor agonists to the micro-delta receptor hetero-oligomer. Br J Pharmacol 2010; 161: 1122-1136.
13. George SR, Fan T, Xie Z, Tse R, Tam V, Varghese G et al. Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. J Biol Chem 2000; 275: 26128-26135.
14. Fan T, Varghese G, Nguyen T, Tse R, O'Dowd BF, George SR. A role for the distal carboxyl tails in generating the novel pharmacology and G protein activation profile of mu and delta opioid receptor hetero-oligomers. J Biol Chem 2005; 280: 38478-38488.
15. Gomes I, Gupta A, Filipovska J, Szeto HH, Pintar JE, Devi LA. A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci USA 2004; 101: 5135-5139.
16. Milan-Lobo L, Whistler JL. Heteromerization of the mu- and delta-opioid receptors produces ligand-biased antagonism and alters mu-receptor trafficking. J Pharmacol Exp Ther 2011; 337: 868-875.
17. Torregrossa MM, Jutkiewicz EM, Mosberg HI, Balboni G, Watson SJ, Woods JH. Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats. Brain Res 2006; 1069: 172-181.
18. Broom DC, Jutkiewicz EM, Folk JE, Traynor JR, Rice KC, Woods JH. Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacology 2002; 26: 744-755.
19. Perrine SA, Hoshaw BA, Unterwald EM. Delta opioid receptor ligands modulate anxiety-like behaviors in the rat. Br J Pharmacol 2006; 147: 864-872.
20. Jutkiewicz EM. The antidepressant -like effects of delta-opioid receptor agonists. Mol Interv 2006; 6: 162-169.
21. Broom DC, Jutkiewicz EM, Rice KC, Traynor JR, Woods JH. Behavioral effects of delta-opioid receptor agonists: potential antidepressants? Jpn J Pharmacol 2002; 90: 1-6.
22. Kastin AJ, Scollan EL, Ehrensing RH, Schally AV, Coy DH. Enkephalin and other peptides reduce passiveness. Pharmacol Biochem Behav 1978; 9: 515-519.
23. Vergura R, Balboni G, Spagnolo B, Gavioli E, Lambert DG, McDonald J et al. Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)- Bid (UFP-512), a novel selective delta opioid receptor agonist. Peptides 2008; 29: 93-103.
24. Baamonde A, Dauge V, Ruiz-Gayo M, Fulga IG, Turcaud S, Fournie-Zaluski MC et al. Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulation. Eur J Pharmacol 1992; 216: 157-166.
25. Pradhan AA, Befort K, Nozaki C, Gaveriaux-Ruff C, Kieffer BL. The delta opioid receptor: an evolving target for the treatment of brain disorders. Trends Pharmacol Sci 2011; 32: 581-590.
26. Scherrer G, Befort K, Contet C, Becker J, Matifas A, Kieffer BL. The delta agonists DPDPE and deltorphin II recruit predominantly mu receptors to produce thermal analgesia: a parallel study of mu, delta and combinatorial opioid receptor knockout mice. Eur J Neurosci 2004; 19: 2239-2248.
27. Gaveriaux-Ruff C, Kieffer BL. Opioid receptor genes inactivated in mice: the highlights. Neuropeptides 2002; 36: 62-71.
28. Oleskevich S, Leck KJ, Matthaei K, Hendry IA. Enhanced serotonin response in the hippocampus of Galphaz protein knock-out mice. Neuroreport 2005; 16: 921-925.
29. Gupta A, Mulder J, Gomes I, Rozenfeld R, Bushlin I, Ong E et al. Increased abundance of opioid receptor heteromers after chronic morphine administration. Sci Signal 2010; 3: ra54.
30. Epstein J, Pan H, Kocsis JH, Yang Y, Butler T, Chusid J et al. Lack of ventral striatal response to positive stimuli in depressed versus normal subjects. Am J Psychiatry 2006; 163: 1784-1790.
31. Forbes EE, Hariri AR, Martin SL, Silk JS, Moyles DL, Fisher PM et al. Altered striatal activation predicting real-world positive affect in adolescent major depressive disorder. Am J Psychiatry 2009; 166: 64-73.
32. Bewernick BH, Hurlemann R, Matusch A, Kayser S, Grubert C, Hadrysiewicz B et al. Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biol Psychiatry 2011; 67: 110-116.
33. Grubert C, Hurlemann R, Bewernick BH, Kayser S, Hadrysiewicz B, Axmacher N et al. Neuropsychological safety of nucleus accumbens deep brain stimulation for major depression: effects of 12-month stimulation. World J Biol Psychiatry 2011; 12: 516-527.
34. Balboni G, Salvadori S, Guerrini R, Negri L, Giannini E, Jinsmaa Y et al. Potent delta-opioid receptor agonists containing the Dmt-Tic pharmacophore. J Med Chem 2002; 45: 5556-5563.
35. Paxinos G, Watson CR. The Rat Brain in Stereotaxic Coordinates. Fourth ed. (Academic Press: New York, NY, USA, 1998.
36. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999; 285: 1569-1572.
37. Mao SC, Lin HC, Gean PW. Augmentation of fear extinction by infusion of glycine transporter blockers into the amygdala. Mol Pharmacol 2009; 76: 369-378.
38. Brebner K, Wong TP, Liu L, Liu Y, Campsall P, Gray S et al. Nucleus accumbens long-term depression and the expression of behavioral sensitization. Science 2005; 310: 1340-1343.
39. Kim J, Lee S, Park H, Song B, Hong I, Geum D et al. Blockade of amygdala metabotropic glutamate receptor subtype 1 impairs fear extinction. Biochem Biophys Res Commun 2007; 355: 188-193.
40. Porsolt RD, Anton G, Blavet N, Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978; 47: 379-391.
41. Lucki I, Singh A, Kreiss DS. Antidepressant-like behavioral effects of serotonin receptor agonists. Neurosci Biobehav Rev 1994; 18: 85-95.
42. Randall-Thompson JF, Pescatore KA, Unterwald EM. A role for delta opioid receptors in the central nucleus of the amygdala in anxiety-like behaviors. Psychopharmacology (Berl) 2010; 212: 585-595.
43. Matsuzaki S, Ikeda H, Akiyama G, Sato M, Moribe S, Suzuki T et al. Role of mu- and delta-opioid receptors in the nucleus accumbens in turning behaviour of rats. Neuropharmacology 2004; 46: 1089-1096.
44. Hawkins MF, Cubic B, Baumeister AA, Barton C. Microinjection of opioid antagonists into the substantia nigra reduces stress-induced eating in rats. Brain Res 1992; 584: 261-265.
45. Braida D, Paladini E, Gori E, Sala M. Naltrexone, naltrindole, and CTOP block cocaine-induced sensitization to seizures and death. Peptides 1997; 18: 1189-1195.
46. Schmidt BL, Tambeli CH, Levine JD, Gear RW. mu/delta Cooperativity and opposing kappa-opioid effects in nucleus accumbens-mediated antinociception in the rat. Eur J Neurosci 2002; 15: 861-868.
47. Gear RW, Levine JD. Nucleus accumbens facilitates nociception. Exp Neurol 2011; 229: 502-506.
48. Xiong W, Yu LC. Involvements of mu- and kappa-opioid receptors in morphineinduced antinociception in the nucleus accumbens of rats. Neurosci Lett 2006; 399: 167-170.
49. Li Y, Li JJ, Yu LC. Anti-nociceptive effect of neuropeptide Y in the nucleus accumbens of rats: an involvement of opioid receptors in the effect. Brain Res 2002; 940: 69-78.
50. Rogoz Z, Skuza G, Leskiewicz M, Budziszewska B. Effects of co-administration of fluoxetine or tianeptine with metyrapone on immobility time and plasma corticosterone concentration in rats subjected to the forced swim test. Pharmacol Rep 2008; 60: 880-888.
51. Tatarczynska E, Klodzinska A, Chojnacka-Wojcik E. Effects of combined administration of 5-HT1A and/or 5-HT1B receptor antagonists and paroxetine or fluoxetine in the forced swimming test in rats. Pol J Pharmacol 2002; 54: 615-623.
52. Berrocoso E, Mico JA. Cooperative opioid and serotonergic mechanisms generate superior antidepressant-like effects in a mice model of depression. Int J Neuropsychopharmacol 2009; 12: 1033-1044.
53. Dulawa SC, Hen R. Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. Neurosci Biobehav Rev 2005; 29: 771-783.
54. Pellow S, Chopin P, File SE, Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985; 14: 149-167.
55. Wang H, Pickel VM. Preferential cytoplasmic localization of delta-opioid receptors in rat striatal patches: comparison with plasmalemmal mu-opioid receptors. J Neurosci 2001; 21: 3242-3250.
56. Pickel VM, Towle AC, Joh TH, Chan J. Gamma-aminobutyric acid in the medial rat nucleus accumbens: ultrastructural localization in neurons receiving monosynaptic input from catecholaminergic afferents. J Comp Neurol 1988; 272: 1-14.
57. Svingos AL, Moriwaki A, Wang JB, Uhl GR, Pickel VM. Ultrastructural immunocytochemical localization of mu-opioid receptors in rat nucleus accumbens: extrasynaptic plasmalemmal distribution and association with Leu5- enkephalin. J Neurosci 1996; 16: 4162-4173.
58. Svingos AL, Clarke CL, Pickel VM. Cellular sites for activation of delta-opioid receptors in the rat nucleus accumbens shell: relationship with Met5-enkephalin. J Neurosci 1998; 18: 1923-1933.
59. Svingos AL, Moriwaki A, Wang JB, Uhl GR, Pickel VM. mu-Opioid receptors are localized to extrasynaptic plasma membranes of GABAergic neurons and their targets in the rat nucleus accumbens. J Neurosci 1997; 17: 2585-2594.
60. Hipolito L, Sanchez-Catalan MJ, Zanolini I, Polache A, Granero L. Shell/core differences in mu- and delta-opioid receptor modulation of dopamine efflux in nucleus accumbens. Neuropharmacology 2008; 55: 183-189.
61. Hirose N, Murakawa K, Takada K, Oi Y, Suzuki T, Nagase H et al. Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens. Neuroscience 2005; 135: 213-225.
62. Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol 1997; 12(Suppl 3): S7-14.
63. Kitamura Y, Yagi T, Kitagawa K, Shinomiya K, Kawasaki H, Asanuma M et al. Effects of bupropion on the forced swim test and release of dopamine in the nucleus accumbens in ACTH-treated rats. Naunyn Schmiedebergs Arch Pharmacol 2010; 382: 151-158.
64. Bosse KE, Jutkiewicz EM, Gnegy ME, Traynor JR. The selective delta opioid agonist SNC80 enhances amphetamine-mediated efflux of dopamine from rat striatum. Neuropharmacology 2008; 55: 755-762.
65. Do Carmo GP, Folk JE, Rice KC, Chartoff E, Carlezon Jr. WA, Negus SS. The selective non-peptidic delta opioid agonist SNC80 does not facilitate intracranial selfstimulation in rats. Eur J Pharmacol 2009; 604: 58-65.
66. Nestler EJ, Carlezon Jr. WA. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006; 59: 1151-1159.
67. Tye KM, Mirzabekov JJ, Warden MR, Ferenczi EA, Tsai HC, Finkelstein J et al. Dopamine neurons modulate neural encoding and expression of depressionrelated behaviour. Nature 2012; 493: 537-541.
68. Alexander B, Warner-Schmidt J, Eriksson T, Tamminga C, Arango-Lievano M, Ghose S et al. Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens. Sci Transl Med 2010; 2: 54ra76.
69. Chaudhury D, Walsh JJ, Friedman AK, Juarez B, Ku SM, Koo JW et al. Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons. Nature 2012; 493: 532-536.
70. Christoffel DJ, Golden SA, Heshmati M, Graham A, Birnbaum S, Neve RL et al. Effects of inhibitor of kappaB kinase activity in the nucleus accumbens on emotional behavior. Neuropsychopharmacology 2012; 37: 2615-2623.